About UniQure
UniQure is a company based in Amsterdam (Netherlands) founded in 1998.. UniQure has raised $111 million across 5 funding rounds from investors including Hercules Capital, European Union and Bristol-Myers Squibb. The company has 209 employees as of December 31, 2024. UniQure has completed 2 acquisitions, including AMT Biopharma and Corlieve Therapeutics. UniQure offers products and services including AMT-130, AMT-191, and Pipeline Programs. UniQure operates in a competitive market with competitors including Denali Therapeutics, Spark Therapeutics, MiRagen, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter Amsterdam, Netherlands
- Employees 209 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Uniqure N.V.
-
Annual Revenue
$27.12 M71.17as on Dec 31, 2024
-
Net Profit
$-239.56 M22.34as on Dec 31, 2024
-
EBITDA
$-171.63 M33.85as on Dec 31, 2024
-
Total Equity Funding
$111 M (USD)
in 5 rounds
-
Latest Funding Round
$534.01 K (USD), Grant
Apr 01, 2021
-
Investors
Hercules Capital
& 3 more
-
Employee Count
209
as on Dec 31, 2024
-
Investments & Acquisitions
AMT Biopharma
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of UniQure
UniQure is a publicly listed company on the NASDAQ with ticker symbol QURE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of UniQure
UniQure offers a comprehensive portfolio of products and services, including AMT-130, AMT-191, and Pipeline Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for Huntington’s Disease through gene editing.
Therapy for Fabry Disease via clinical trials.
Develops therapies for ALS and other diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
26 people
Software Development Team
21 people
Product Management Team
8 people
Human Resources and Administration
7 people
Finance and Accounting
5 people
Operations Team
4 people
Senior Team
4 people
Legal and Compliance
3 people
Unlock access to complete
Funding Insights of UniQure
UniQure has successfully raised a total of $111M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $534.01 thousand completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $534,014
-
First Round
First Round
(09 Jul 2013)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Grant - UniQure | Valuation |
investors |
|
| Apr, 2015 | Amount | Post-IPO - UniQure | Valuation |
investors |
|
| Apr, 2015 | Amount | Private Equity Round - UniQure | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in UniQure
UniQure has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, European Union and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by UniQure
UniQure has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include AMT Biopharma and Corlieve Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for neurological disorders are developed using AAV gene delivery.
|
2019 | ||||
|
Human gene-based therapies are developed using AAV vectors.
|
2011 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - UniQure
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Uniqure Comparisons
Competitors of UniQure
UniQure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Spark Therapeutics, MiRagen, Poseida Therapeutics and Juno Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Uniqure
Frequently Asked Questions about UniQure
When was UniQure founded?
UniQure was founded in 1998 and raised its 1st funding round 15 years after it was founded.
Where is UniQure located?
UniQure is headquartered in Amsterdam, Netherlands.
Who is the current CEO of UniQure?
Matthew Kapusta is the current CEO of UniQure.
Is UniQure a funded company?
UniQure is a funded company, having raised a total of $111M across 5 funding rounds to date. The company's 1st funding round was a Private Equity Round of $53M, raised on Jul 09, 2013.
How many employees does UniQure have?
As of Dec 31, 2024, the latest employee count at UniQure is 209.
What is the annual revenue of UniQure?
Annual revenue of UniQure is $27.12M as on Dec 31, 2024.
What does UniQure do?
UniQure was founded in 1998 in Amsterdam, Netherlands, as a biotechnology firm focused on adeno-associated virus-based gene therapies. Treatments are developed through its platform for conditions including lipoprotein lipase deficiency with Glybera, hemophilia B via AMT-060, congestive heart failure using S100A1, acute intermittent porphyria with AMT-021, Sanfilippo B syndrome through AMT-110, and Parkinsons disease employing AAV2glial cell line-derived neurotrophic factor. Operations center on advancing these therapies across multiple disease areas.
Who are the top competitors of UniQure?
UniQure's top competitors include Spark Therapeutics, Juno Therapeutics and Alnylam.
What products or services does UniQure offer?
UniQure offers AMT-130, AMT-191, and Pipeline Programs.
Is UniQure publicly traded?
Yes, UniQure is publicly traded on NASDAQ under the ticker symbol QURE.
How many acquisitions has UniQure made?
UniQure has made 2 acquisitions, including AMT Biopharma, and Corlieve Therapeutics.
Who are UniQure's investors?
UniQure has 4 investors. Key investors include Hercules Capital, European Union, Bristol-Myers Squibb, and Coller Capital.
What is UniQure's ticker symbol?
The ticker symbol of UniQure is QURE on NASDAQ.